DZ Bank’s Royalty Pharma RPRX Stock Holding History

DZ Bank’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-175,000	Closed	-$6.84M	–	1070
2022 Q1	$6.84M	Buy	+175,000	New	+$6.87M	0.01%	426

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DZ Bank's RPRX Position: Q4 2024 in Review

DZ Bank sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 3,200 shares — an estimated $90.5K sold.

DZ Bank first reported a position in RPRX in Q4 2020 and held it in 12 quarters. The position peaked at $6.44M in Q4 2020. 416 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

DZ Bank reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
DZ Bank sold 3,200 Royalty Pharma shares in Q4 2024, an estimated $90.5K.
DZ Bank first reported a position in Royalty Pharma in Q4 2020 and held it in 12 quarters.
DZ Bank's Royalty Pharma position peaked at $6.44M in Q4 2020.
416 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on DZ Bank's 13F filing for Q4 2024, filed 14 Feb 2025.